DRREDDY · Healthcare
Dr. Reddy's Laboratories Ltd. reported revenue of ₹7,114 cr for January to March 2024, — on the year and −1.7% on the quarter.
Operating profit (EBITDA) was ₹1,831 cr, a margin of 25.7%, — on the year and −222 bps on the quarter.
Net profit was ₹1,310 cr, — on the year and −5.1% on the quarter, with earnings per share of ₹15.70.
On earnings per share of ₹66.90 over the last four quarters, the stock at ₹1,229.70 trades at 18.4 times trailing earnings.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow filed with this quarter, the auditor's review, segment results, one-off items line by line and what management said on the call.
No check fired. That is a statement about the checks below, not a verdict on the company.
Could not run on this quarter: Headline vs core profit, Exceptional items that recur, Operating margin on the year, Depreciation falling, Finance cost rising, Swing to loss or profit, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
This quarter's filing carries a balance sheet and a cash flow statement. The cash, receivables and borrowing checks run once the filing read is in.
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹6,903 cr | ₹7,237 cr | ₹7,114 cr | ₹7,696 cr | ₹8,038 cr | ₹8,381 cr | ₹8,528 cr | ₹8,572 cr | ₹8,828 cr | ₹8,753 cr | ₹7,546 cr | ₹8,100 cr |
| YoY | — | — | — | +14% | +16% | +16% | +20% | +11% | +10% | +4% | −12% | −6% |
| EBITDA margin | 29.1% | 28.0% | 25.7% | 27.7% | 25.8% | 27.1% | 23.4% | 25.4% | 22.8% | 21.6% | 5.1% | 10.6% |
| Other income, % of PBT | 17% | 12% | 13% | 10% | 16% | 8% | 26% | 15% | 19% | 18% | 240% | 64% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 23% | 24% | 18% | 26% | 30% | 25% | 21% | 26% | 23% | 23% | −11% | 21% |
| Net profit | ₹1,482 cr | ₹1,381 cr | ₹1,310 cr | ₹1,392 cr | ₹1,342 cr | ₹1,404 cr | ₹1,587 cr | ₹1,410 cr | ₹1,337 cr | ₹1,190 cr | ₹221 cr | ₹436 cr |
| YoY | — | — | — | −1% | −9% | +2% | +21% | +1% | −0% | −15% | −86% | −69% |
| Core profit YoY | — | — | — | +1% | +0% | +7% | +5% | −4% | −12% | −26% | −119% | −88% |
| EPS | ₹17.77 | ₹16.56 | ₹15.70 | ₹16.69 | ₹15.05 | ₹16.94 | ₹19.09 | ₹16.99 | ₹16.14 | ₹14.50 | ₹2.65 | ₹5.32 |
| Flags | · | · | · | ✓ | 1 | ✓ | 1 | ✓ | 1 | 1 | 4 | 2 |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Dr. Reddy's Laboratories Ltd. reported revenue of ₹7,114 cr (— on the year) and net profit of ₹1,310 cr (— on the year) for January to March 2024.
None of the 2 checks that could run raised a question.
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.